secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2026-08-13T20:02:19+00:00
Accession:  0001493152-26-037737
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daré launches first product Flora Sync LF5, Q2 revenue $0.2M, positive Ovaprene data
--------------------------------------------------------------------------------

- Launched Flora Sync LF5, first directly commercialized product; revenue began in July 2026.
- Q2 2026 total revenue $0.2M vs $(0.02)M YoY; cost of revenues $0.3M.
- Cash and equivalents ~$12.6M; working capital deficit ~$0.2M.
- Positive interim Phase 3 Ovaprene results; DSMB recommends continue without modification.
- DARE to PLAY Sildenafil Cream on track for Q3 2026 dispensing and revenue; prescriptions accepted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000149315226037737/0001493152-26-037737-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000149315226037737/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037737

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer